CN114096530A - Pharmaceutical composition of compound and preparation method thereof - Google Patents

Pharmaceutical composition of compound and preparation method thereof Download PDF

Info

Publication number
CN114096530A
CN114096530A CN202180004442.1A CN202180004442A CN114096530A CN 114096530 A CN114096530 A CN 114096530A CN 202180004442 A CN202180004442 A CN 202180004442A CN 114096530 A CN114096530 A CN 114096530A
Authority
CN
China
Prior art keywords
pharmaceutical composition
exp3174
ahu377
complex
crospovidone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180004442.1A
Other languages
Chinese (zh)
Other versions
CN114096530B (en
Inventor
蔡燕霞
叶冠豪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Salubris Pharmaceuticals Co Ltd
Original Assignee
Shenzhen Salubris Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Salubris Pharmaceuticals Co Ltd filed Critical Shenzhen Salubris Pharmaceuticals Co Ltd
Priority to CN202211269494.4A priority Critical patent/CN116036079A/en
Publication of CN114096530A publication Critical patent/CN114096530A/en
Application granted granted Critical
Publication of CN114096530B publication Critical patent/CN114096530B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Belongs to the technical field of medicinal preparations, relates to a pharmaceutical composition of a compound and a preparation method thereof, and particularly relates to a pharmaceutical composition of a compound of an angiotensin II receptor antagonist metabolite and an NEP inhibitor and a preparation method thereof.

Description

Pharmaceutical composition of compound and preparation method thereof Technical Field
The invention belongs to the technical field of medicinal preparations, relates to a pharmaceutical composition of a compound and a preparation method thereof, and particularly relates to a pharmaceutical composition of a compound of an angiotensin II receptor antagonist metabolite and an NEP inhibitor and a preparation method thereof.
Background
Hypertension is a clinical syndrome mainly manifested by increased systemic arterial pressure, and is the most common cardiovascular disease. Hypertension is mostly slow in onset and lacks special clinical manifestations, resulting in delayed diagnosis, which is only found when blood pressure is measured or when complications such as heart, brain, kidney, etc. occur. There is a close causal relationship between long-term hypertension and the risk of cardiovascular and cerebrovascular disease onset and death.
Statistically, hypertension is currently uncontrolled in more than a billion people worldwide, and is expected to increase to 15 billion by 2030. In China, the results of Chinese hypertension investigation (CHS) in 2012-2015 show that: the prevalence rate of hypertension of adults more than or equal to 18 years old in China is 27.9 percent (the weight rate is 23.2 percent), the awareness rate, the treatment rate and the control rate are respectively 51.6 percent, 45.8 percent and 16.8 percent, and the treatment control rate is 37.5 percent. The incidence of hypertension is on the rising trend, and according to statistics, the number of cardiovascular disease patients in China is about 2.9 hundred million (reports 2013 on cardiovascular disease in China). If hypertension cannot be effectively controlled and treated, coronary arteriosclerosis, coronary heart disease and angina pectoris can be caused, and severe complications such as hypertensive heart disease and heart failure can also be caused. In addition, long-term hypertension can cause damage to organs such as kidney, brain, and cardiovascular system.
Heart failure is a severe manifestation or late stage of various heart diseases, is an important content for preventing and treating chronic cardiovascular diseases worldwide, and the mortality and the hospitalization rate are high. European and American epidemiological data show that the prevalence rate of adult heart failure is 1.5-2.0%, and the prevalence rate of heart failure is increased along with the increase of age, and the prevalence rate of people of more than or equal to 70 years old is more than or equal to 10%. The Chinese epidemiological survey in 2003 shows that the heart failure prevalence rate of adults 35-74 years old in China is 0.9%. The Chinese cardiovascular disease report 2016 proposes that the cardiovascular disease prevalence rate is in the continuously rising stage in China, and the cardiovascular disease mortality rate is the first place and higher than that of tumors and other diseases. The aging of the population of China is aggravated, the incidence of chronic diseases such as coronary heart disease, hypertension, diabetes, obesity and the like is on the rise, and the improvement of the medical level prolongs the life cycle of heart disease patients, so that the heart failure morbidity of China is on the continuous rise. The domestic 10714 inpatient heart failure patients were investigated and shown: 1980. the fatality rates during hospitalization of heart failure patients in 1990 and 2000 were 15.4%, 12.3% and 6.2%, respectively, with the main causes of death being left heart failure (59%), arrhythmia (13%) and sudden cardiac death (13%). The China-HF study showed that the mortality rate of hospitalized heart failure patients was 4.1%.
WO2007056546a1 discloses a sodium salt complex (LCZ696) of Valsartan (Valsartan) -savibiril (AHU 377) and a preparation method thereof, which was purchased and marketed in china in 2017 under the trade name: nuoxin pill
Figure PCTCN2021100465-APPB-000001
(the product name is foreign
Figure PCTCN2021100465-APPB-000002
2015) for heart failure. The molecular structural unit is as follows:
Figure PCTCN2021100465-APPB-000003
patent WO2009061713 discloses a formulation of sabotara valsartan sodium and a process for its preparation by mixing a therapeutic agent with at least one pharmaceutically acceptable excipient, a formulation of multiple formulations is disclosed, followed by compression of the mixture either directly with suitable equipment such as a tablet press or by compressing the mixture with suitable equipment such as a roller compactor.
Has been on the market
Figure PCTCN2021100465-APPB-000004
The prescription comprises microcrystalline cellulose, low-substituted hydroxypropyl cellulose, crospovidone, magnesium stearate, talcum powder and colloidal silicon dioxide. The film coat comprises hydroxypropyl methylcellulose, titanium dioxide (E171), polyethylene glycol 4000, talcum powder and iron oxide red (E172).
In addition, WO2017125031a1 discloses a series of complexes of angiotensin receptor antagonist metabolites (EXP3174) and NEP inhibitors (securitil) and shows some effect on heart failure HFpEF with preserved ejection fraction, whose molecular structural units are as follows:
Figure PCTCN2021100465-APPB-000005
however, due to the difference of the compound composition, how to find a preparation scheme which is suitable for clinical use is crucial, and further research and development are needed.
Disclosure of Invention
In view of the problems of the prior art, the invention provides a novel compound pharmaceutical composition and a preparation method thereof,
the invention is realized by the following technical scheme, and the pharmaceutical composition of the compound comprises the following structural units:
(aEXP3174·bAHU377)·xCa·nA
wherein a and b are 1: 0.25-4; x is a number between 0.5 and 3; a refers to water, methanol, ethanol, 2-propanol, acetone, ethyl acetate, methyl-tert-butyl ether, acetonitrile, toluene, dichloromethane; n is a number between 0 and 3;
the pharmaceutical composition contains one or a mixture of more than two of low-substituted hydroxypropyl cellulose, crospovidone, carboxymethyl starch sodium, croscarmellose sodium and pregelatinized starch in any proportion, and the usage amount of the pharmaceutical composition is 4-50%; and one or more other adjuvants.
As a preferable technical scheme of the invention, the pharmaceutical composition contains low-substituted hydroxypropyl cellulose and crospovidone, the usage amount of the low-substituted hydroxypropyl cellulose in the pharmaceutical composition is preferably 17% -30%, and the usage amount of the crospovidone in the pharmaceutical composition is preferably 8% -20%.
As a preferred technical scheme of the invention, the preferred ratio of the low-substituted hydroxypropyl cellulose to the crospovidone is 1: 1-3: 1, the sum of the weight of the two is preferably 25 to 40 percent of the dosage in the pharmaceutical composition. More preferably, when the proportion of the compound in the pharmaceutical composition is 25% -30%, the proportion of the low-substituted hydroxypropyl cellulose and the crospovidone is 1.75: 1-2.25: 1, more preferably 2: 1.
as a preferable technical scheme, the pharmaceutical composition contains carboxymethyl starch sodium, croscarmellose sodium and crospovidone, wherein the using amount of the carboxymethyl starch sodium in the pharmaceutical composition is 4% -12%, the using amount of the croscarmellose sodium in the pharmaceutical composition is 4% -12%, and the using amount of the crospovidone in the pharmaceutical composition is 4% -12%; the sum of the weight of the three components is preferably 15 to 35 percent of the dosage in the pharmaceutical composition. More preferably, when the proportion of the complex in the pharmaceutical composition is 40% -50%, the amount of the sodium carboxymethyl starch in the pharmaceutical composition is 8-12%, the amount of the croscarmellose sodium in the pharmaceutical composition is 8-12%, and the amount of the crospovidone in the pharmaceutical composition is 8-12%.
In the invention, the low-substituted hydroxypropyl cellulose with the proportion has large surface area and porosity, strong water absorption expansibility and obvious disintegration effect; moreover, crospovidone of the foregoing ratio has good fluidity in the present invention, rapidly exhibits capillary activity and excellent hydration ability in water, and also has good disintegration properties. The low-substituted hydroxypropyl cellulose and the crospovidone are used in combination, so that the product can be rapidly disintegrated in a dissolution medium to achieve the effect of rapid release.
As a preferred technical solution of the present invention, the one or more other auxiliary materials include one or more fillers, lubricants, coating agents, and the like.
As a preferable technical scheme of the invention, the filler comprises one or a mixture of more than two of microcrystalline cellulose, lactose, mannitol and calcium hydrophosphate in any proportion, and the using amount of the filler is 16-60 percent of the weight of the pharmaceutical composition, preferably 17-45 percent of the weight of the pharmaceutical composition.
In a preferred embodiment of the present invention, the filler comprises a mixture of microcrystalline cellulose and lactose, and the mass ratio of microcrystalline cellulose to lactose is preferably 1: 1-5: 1, preferably the total mass of microcrystalline cellulose and lactose is 16% to 60%, more preferably 17% to 45% by weight of the pharmaceutical composition.
As a preferred technical scheme of the invention, the lactose is preferably anhydrous lactose, the anhydrous lactose and the microcrystalline cellulose form more than about 40 percent of the total preparation part, the anhydrous lactose and the microcrystalline cellulose have good fluidity and compressibility as fillers in the prescription, the properties are stable, and the prepared tablet has smooth appearance and better hardness and disintegration. Can also be used for the direct compression process and the dry granulation process.
As a preferred embodiment of the present invention, when the proportion of the complex in the pharmaceutical composition is 25% to 30% (specifically, the complex is 60, 120mg in terms of free acid), the mass ratio of the microcrystalline cellulose to the lactose is 1.5: 1-5: 1, preferably the total mass of microcrystalline cellulose and lactose is 17-45% by weight of the pharmaceutical composition.
As a preferred embodiment of the present invention, when the proportion of the complex in the pharmaceutical composition is 40% to 50% (specifically, 240mg of the complex as free acid), the mass ratio of the microcrystalline cellulose to the lactose is 1.8: 1-2.2: 1 (such as 1.9: 1, 2:1, 2.1: 1, etc.), preferably the total mass of microcrystalline cellulose and lactose is 17% -45% of the weight of the pharmaceutical composition.
As a preferred embodiment of the invention, the complex is prepared by reacting the free acid C with water46H 50ClN 7O 7Calculated by weight) of the pharmaceutical composition is 20-50 percent, and the specific using amount is preferably 30mg, 60mg, 90mg, 120mg, 150mg, 180mg, 210mg, 240mg, 270mg, 300mg and the like.
As a preferable technical scheme of the invention, the lubricant comprises one or a mixture of more than two of silicon dioxide, stearic acid, magnesium stearate, polyethylene glycol and hydrogenated castor oil, and the mass of the lubricant is 1-3% of the weight of the pharmaceutical composition.
According to a preferred technical scheme of the invention, the lubricant is a composition of silicon dioxide and magnesium stearate, the silicon dioxide mainly plays a role of a flow aid and has a lubricating function, and the magnesium stearate belongs to a hydrophobic material, is easily mixed with the granules uniformly and attached to the surfaces of the granules, and can reduce the friction force between the granules and a die. The two are used in the pharmaceutical composition according to the proportion, so that the fluidity of the materials can be obviously improved, and the tablet surface is smooth and beautiful after tabletting.
Except for other descriptions, the sum of the percentages of the raw materials and the auxiliary materials in the pharmaceutical composition is 95-100%, and the use amounts are mass use amounts.
As a preferred embodiment of the present invention, the coating agent comprises any gastric coating. Specifically, for example, the gastric coating includes 85G640059-CN, and the gastric coating is coated with a solvent mixture such as water (preferably, the gastric coating agent and purified water are mixed at a mass ratio of 1: 5 to 1: 8), and the weight of the coated gastric coating is increased by about 0.1 to 4%.
In the composition of the compound of the invention, the molecular formula of EXP3174 is C22H 21ClN 6O 2A molecular weight of about 436.9; AHU377 has a molecular formula of C24H 29NO 5And a molecular weight of about 411.5.
Said complexes of said drugs can be obtained by methods known in the art, wherein the complexes disclosed in WO2017125031a1 and the methods for their preparation are incorporated in the present invention.
As a more preferred embodiment of the present invention, the values of a: b include 1:0.25, 1:0.5, 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1: 4.
In a more preferred embodiment of the present invention, the structural units of the complex are as follows:
(EXP3174·AHU377)·xCa·nH 2O
or
Figure PCTCN2021100465-APPB-000006
Wherein x is a number between 0.5 and 2; n is a number between 0 and 3.
In a more preferred embodiment of the present invention, x is 0.5, 1, 1.5, or 2.
In a more preferred embodiment of the present invention, the structural units of the complex are as follows:
(EXP3174·AHU377)·1.5Ca·nH 2O
or
(EXP3174·AHU377)·2Ca·nH 2O
Wherein n is any value between 1 and 3.
In a more preferred embodiment of the present invention, n includes 0.5, 1, 1.5, 2, 2.5 and 3.
As a more preferred embodiment of the present invention, the complex comprises:
(EXP3174·AHU377)·1.5Ca·1H 2O；
(EXP3174·AHU377)·1.5Ca·1.5H 2O；
(EXP3174·AHU377)·1.5Ca·2H 2O；
(EXP3174·AHU377)·1.5Ca·2.5H 2O；
(EXP3174·AHU377)·1.5Ca·3H 2O；
(EXP3174·AHU377)·2Ca·1H 2O；
(EXP3174·AHU377)·2Ca·1.5H 2O；
(EXP3174·AHU377)·2Ca·2H 2O；
(EXP3174·AHU377)·2Ca·2.5H 2O；
(EXP3174·AHU377)·2Ca·3H 2O。
it will be understood by those skilled in the art that in the unit cell of the supramolecular complex (complex), the alisartan medoxomil metabolite (EXP3174), AHU377, calcium ion (Ca)2+) And solvent molecules will fill in it in the form of several building blocks.
The supramolecular complex (complex) of the present invention is distinguished from a mixture of two active ingredients obtained by simple physical mixing. The molecule of the complex is combined with EXP3174 and AHU377 and pharmaceutically acceptable calcium cation through non-covalent bond to obtain a supramolecular complex (complex), the non-covalent bond is well known to those skilled in the art and includes but is not limited to hydrogen bond, coordination bond, ionic bond and the like, the XRD spectrum of the obtained supramolecular complex (complex) is obviously different from the XRD spectrum of EXP3174 and AHU377 calcium salt, the solubility of the supramolecular complex (complex) in each solvent (such as water, ethanol-water and the like) is also obviously different, and other physicochemical properties such as hygroscopicity, melting point, infrared spectrum and the like are obviously different.
The pharmaceutical composition is a solid formulation suitable for oral administration, preferably a tablet or capsule for oral administration.
The invention further provides a preparation method of the pharmaceutical composition, the raw and auxiliary materials are prepared by a direct compression process or a dry granulation process and then tableted, and then the coating agent is adopted for coating, so that the coated pharmaceutical composition is obtained.
The invention further provides the application of the pharmaceutical composition in medicines for preventing and/or treating hypertension, heart failure, hypertension and heart failure.
The beneficial effects of the invention compared with the prior art comprise:
(1) the embodiment of the invention can effectively ensure the disintegration and dissolution of the medicine and has good granulation fluidity and other effects.
(2) Clinical verification shows that the medicine composition can effectively reach the in vivo administration concentration, and is applied to medicines for preventing and/or treating hypertension, heart failure, hypertension and heart failure;
(3) the invention greatly reduces the raw and auxiliary material composition of the prescription, has simple process, is environment-friendly and economic, and is beneficial to large-scale industrialized application.
(4) The invention effectively controls the tablet weight under the condition that the active ingredients of the pharmaceutical composition have higher ratio, ensures the dissolution and the effect of the medicine and is beneficial to the clinical use of the medicine.
Detailed Description
The present invention will be described in further detail with reference to examples, but the embodiments of the invention are not limited thereto.
Example 1
Preparation of AHU377 free acid:
2.1g of AHU377 calcium salt, 40mL of isopropyl acetate, was placed in a 250mL single-neck flask, and 4.5mL of 2mol/L hydrochloric acid was added thereto at room temperature and the mixture was stirred to dissolve. Separating, collecting an organic layer, and washing the organic layer twice by using 20mL of water; decompression desolventizing at 35 ℃ to obtain AHU377 free acid.
Example 2
Preparation of the complex: (prepared according to example 2 of patent WO2017125031A 1)
Figure PCTCN2021100465-APPB-000007
2.36g of AHU377 free acid obtained according to the method of example 1, EXP 31742 g and 40mL of acetone were added to a 250mL three-necked flask at room temperature and dissolved; adding calcium hydroxide solid and 1mL of water at room temperature, stirring at room temperature for 10h, adding 40mL of acetone, reacting for 8h, filtering with Buchner funnel under nitrogen protection, and adding acetone to the solidRinsing to obtain white solid, vacuum drying at 35 deg.C for 8 hr to obtain solid 3.5g (EXP 3174. AHU377)3-·1.5Ca 2+·2.5H 2And O, the purity is 99 percent by HPLC detection. The test was repeated to obtain sufficient dose for the pharmacodynamic test.
Example 3
Preparation of the complex: (prepared according to example 3 of patent WO2017125031A 1)
Figure PCTCN2021100465-APPB-000008
2.36g of AHU377 free acid obtained according to the method of example 1, EXP 31742 g and 40mL of acetone were added to a 250mL three-necked flask at room temperature and dissolved; adding calcium hydroxide solid and 0.6mL of water at room temperature in an equivalent amount of AHU 3771.6, stirring at 35 ℃ for 6h, adding 40mL of acetone, reacting for 8h, filtering with a Buchner funnel under the protection of nitrogen, leaching the solid with acetone to obtain a white solid, drying at 50 ℃ for 8h in vacuum, and drying to obtain 3.1g of solid (EXP 3174. AHU377)3-·1.5Ca 2+·2H 2And O. The test was repeated to obtain sufficient dose for the pharmacodynamic test.
Example 4
Referring to the preparation methods of examples 2 and 3, the following complexes were prepared, respectively:
(EXP3174·AHU377)·1.5Ca·1H 2O；
(EXP3174·AHU377)·1.5Ca·1.5H 2O；
(EXP3174·AHU377)·1.5Ca·3H 2O；
(EXP3174·AHU377)·2Ca·1H 2O；
(EXP3174·AHU377)·2Ca·1.5H 2O；
(EXP3174·AHU377)·2Ca·2H 2O；
(EXP3174·AHU377)·2Ca·2.5H 2O；
(EXP3174·AHU377)·2Ca·3H 2O。
EXAMPLE 5 disintegrant and selection of its amount
By measuring the dissolution curve of the pH6.8 medium, the types of different disintegrants are inspected, and the optimal disintegrant dosage is screened. The contents of the prescription design are shown in Table 1, and the results of the dissolution curves are shown in Table 2.
TABLE 1 experiments with different disintegrating agents and dosage formulations
Figure PCTCN2021100465-APPB-000009
TABLE 2 results of the dissolution curves of different disintegrants and dosages
Figure PCTCN2021100465-APPB-000010
As can be seen from the selection result of the disintegrating agent, the use of the low-substituted hydroxypropyl cellulose and the crospovidone can promote the dissolution more than the use of the low-substituted hydroxypropyl cellulose alone, and when the use amounts of the low-substituted hydroxypropyl cellulose and the crospovidone respectively reach 17.8% and 8.9%, the dissolution can reach more than 85% in 15 min.
Therefore, the preferred usage amount of the low-substituted hydroxypropyl cellulose in the pharmaceutical composition is 17% -30%, the usage amount of the crospovidone in the pharmaceutical composition is 8% -20%, and the preferred usage amount of the low-substituted hydroxypropyl cellulose and the crospovidone in the pharmaceutical composition is 25% -40%.
EXAMPLE 6 Filler and selection of amount thereof
Based on example 5, the filling agent in the preparation is selected from crystalline cellulose (Type102) and anhydrous lactose (DTHV). Experimental results show that fillers with different proportions can influence the disintegration and dissolution conditions of a tablet core, and proper prescription proportions are screened out by combining disintegration time and a dissolution curve of a medium with pH6.8, and the specific formula proportions are shown in Table 3. The mixture of the two fillers can ensure that the appearance, weight difference and friability of the tablet core meet the requirements.
TABLE 3 formulation of microcrystalline cellulose/lactose in different ratios
Figure PCTCN2021100465-APPB-000011
TABLE 4 results of the study of the disintegration time of microcrystalline cellulose/lactose in different ratios
Figure PCTCN2021100465-APPB-000012
TABLE 5 results of a study of the dissolution curves of microcrystalline cellulose/lactose at different ratios
Figure PCTCN2021100465-APPB-000013
In addition, the result of investigation of the flowability of the mixed powder is as follows: the ratio of microcrystalline cellulose to lactose is 2:1, the angle of repose (degree) is about 40 degrees, and the requirement of fluidity can be met.
Because the ratio of microcrystalline cellulose to lactose is 6: at 1, the tablet thickness is thicker, which may affect swallowing and compliance effects.
From the above results, it is found that the mass ratio of microcrystalline cellulose to anhydrous lactose is more preferably 1: 1-5: 1, the total mass of the microcrystalline cellulose and the lactose is preferably 18 to 60 percent of the weight of the pharmaceutical composition, the disintegration time is fast, and the fast dissolution effect can be obtained, and more preferably, the mass ratio of the microcrystalline cellulose to the lactose is 1.5: 1-5: 1, the dissolution effect is more than or equal to 85 percent within 30 min.
Example 7 the pharmacokinetics of different in vitro dissolution samples in animals was investigated.
By the preferred embodiment of examples 5 and 6, three different samples were prepared and tested for canine PK, the specific formulation is shown in table 6, and the dissolution profile results are shown in table 7.
TABLE 6 different prescription compositions
Figure PCTCN2021100465-APPB-000014
The enteric coating formula comprises: eudragit L30D-55, talcum powder, triethyl citrate and purified water according to the mass ratio of 1: 6, coating after mixing, and increasing the weight by about 3 percent after coating.
TABLE 7 in vitro dissolution results for different formulations
Figure PCTCN2021100465-APPB-000015
As a result: since the enteric coating was selected for the 3C batch, the enteric coating film was not broken in an acidic medium at ph5.5 or less, and therefore, the dissolution profiles of the 3C batch tablets at ph1.2 and ph5.0 were not examined.
Dog PK tests were performed using the bulk drug suspensions as controls and the 3A, 3B and 3C samples to investigate the pharmacokinetics of the in vivo beagle dogs for formulations with different in vitro dissolution profiles, and the results are shown in table 8.
TABLE 8 in vivo pharmacokinetic results in beagle dogs for different prescription samples
Figure PCTCN2021100465-APPB-000016
Figure PCTCN2021100465-APPB-000017
Note: LBQ657 is active metabolite of Shakubaqu.
From the above results, it can be seen that, compared with the suspension, the F values of the three formula tablets of the sakubaqu are all above 90%, which indicates that the sakubaqu is mainly absorbed at the far end of the small intestine, while the bioavailability of the EXP3174 enteric-coated tablet is only about 60% of that of the suspension, and the F values of the other 2 groups of enteric-coated tablets are all above 90%, which indicates that the EXP3174 is absorbed at the near end and the far end of the small intestine.
The above experiment shows that the enteric coated samples have reduced absorption compared to the suspension, so we chose gastric coating. Specifically, for example, a gastric coating comprising 85G640059-CN, which is coated with a solvent mixture such as water, may be added to the coating in an amount of about 0.1% to about 4%.
The present invention further provides the following preferred examples based on the technical means of the above experimental examples 5 to 7.
Example 8
The compound obtained in the embodiment 3 is adopted as a raw material medicine, and the compound pharmaceutical composition and the preparation method thereof comprise the following steps:
Figure PCTCN2021100465-APPB-000018
Figure PCTCN2021100465-APPB-000019
the preparation method comprises the following steps: mixing the raw materials and auxiliary materials, and directly pressing.
Coating material film coating premix (gastric soluble type 295F640025-CN) and purified water according to the mass ratio of 1: 7 and coating the resulting tablets by direct compression with a powder mixture (wherein the purified water used for coating is removed after coating by drying) to obtain coated tablets, which are coated to a weight gain of about 3%.
Example 9
The compound obtained in the embodiment 3 is adopted as a raw material medicine, and the compound pharmaceutical composition and the preparation method thereof comprise the following steps:
Figure PCTCN2021100465-APPB-000020
the production process comprises the following steps: the preparation method comprises the following steps: dry granulating the raw and auxiliary materials, and tabletting;
coating material film coating premix (gastric soluble type 295F640025-CN) and purified water according to the mass ratio of 1: 7 coating, granulating and tabletting the obtained tablets (wherein purified water used for coating is finally removed by drying after coating) after mixing to obtain coated tablets, and the weight is increased by about 3% after coating.
Example 10
The compound obtained in the embodiment 3 is adopted as a raw material medicine, and the compound pharmaceutical composition and the preparation method thereof comprise the following steps:
Figure PCTCN2021100465-APPB-000021
the production process comprises the following steps: the preparation method comprises the following steps: mixing the raw materials and auxiliary materials and performing direct pressing;
coating material film coating premix (gastric soluble type 295F640025-CN) and purified water according to the mass ratio of 1: 6 mixing, coating the powder mixture and direct-compressing the resulting tablets (wherein the purified water used for coating is dried after coating and finally removed) to obtain coated tablets, which are coated to a weight gain of about 3%.
Example 11
The compound obtained in the embodiment 3 is adopted as a raw material medicine, and the compound pharmaceutical composition and the preparation method thereof comprise the following steps:
Figure PCTCN2021100465-APPB-000022
the production process comprises the following steps: the preparation method comprises the following steps: dry granulating the raw and auxiliary materials, and tabletting;
coating material film coating premix (gastric soluble type 295F640025-CN) and purified water according to the mass ratio of 1: 6 coating, granulating and tabletting the obtained tablets (wherein purified water used for coating is finally removed by drying after coating) after mixing to obtain coated tablets, and the weight is increased by about 3% after coating.
Example 12
The compound obtained in the embodiment 3 is adopted as a raw material medicine, and the compound pharmaceutical composition and the preparation method thereof comprise the following steps:
Figure PCTCN2021100465-APPB-000023
the production process comprises the following steps: the preparation method comprises the following steps: mixing the raw materials and auxiliary materials and performing direct pressing;
coating material film coating premix (gastric soluble type 295F640025-CN) and purified water according to the mass ratio of 1: 6 mixing, coating the powder mixture and direct-compressing the resulting tablets (wherein the purified water used for coating is dried after coating and finally removed) to obtain coated tablets, which are coated to a weight gain of about 3%.
Example 13
The compound obtained in the embodiment 3 is adopted as a raw material medicine, and the compound pharmaceutical composition and the preparation method thereof comprise the following steps:
Figure PCTCN2021100465-APPB-000024
Figure PCTCN2021100465-APPB-000025
the production process comprises the following steps: the preparation method comprises the following steps: dry granulating the raw and auxiliary materials, and tabletting;
coating material film coating premix (gastric soluble type 295F640025-CN) and purified water according to the mass ratio of 1: 6 coating, granulating and tabletting the obtained tablets (wherein purified water used for coating is finally removed by drying after coating) after mixing to obtain coated tablets, and the weight is increased by about 3% after coating.
Example 14
The compound obtained in the embodiment 3 is adopted as a raw material medicine, and the compound pharmaceutical composition and the preparation method thereof comprise the following steps:
Figure PCTCN2021100465-APPB-000026
the production process comprises the following steps: the preparation method comprises the following steps: dry granulating the raw and auxiliary materials, and tabletting;
coating material film coating premix (gastric soluble type 295F640025-CN) and purified water according to the mass ratio of 1: 6 coating, granulating and tabletting the obtained tablets (wherein purified water used for coating is finally removed by drying after coating) after mixing to obtain coated tablets, and the weight is increased by about 3% after coating.
Example 15
The compound obtained in the embodiment 3 is adopted as a raw material medicine, and the compound pharmaceutical composition and the preparation method thereof comprise the following steps:
Figure PCTCN2021100465-APPB-000027
the production process comprises the following steps: the preparation method comprises the following steps: dry granulating the raw and auxiliary materials, and tabletting;
coating material film coating premix (gastric soluble type 295F640025-CN) and purified water according to the mass ratio of 1: 6 coating, granulating and tabletting the obtained tablets (wherein purified water used for coating is finally removed by drying after coating) after mixing to obtain coated tablets, and the weight is increased by about 3% after coating.
Note:athe amount of the complex described in examples 8 to 15 is expressed as the anhydrous free acid C46H 50ClN 7O 7And (6) counting.
The dissolution effect of the previous examples is as follows:
Figure PCTCN2021100465-APPB-000028
the dissolution of each example meets the standard requirements and demonstrates adequate drug exposure in animal experiments.
Examples 16 to 23
Examples 16-23 were in accordance with the recipes of examples 8-15, respectively, except that the drug substance used was the complex of example 2a。
Note:athe amount of the complex is expressed as the anhydrous free acid C46H 50ClN 7O 7And (6) counting.
Example 24 phase I clinical trials were conducted using the pharmaceutical composition of example 8
The complex tablets of the invention have completed single-center, randomized, double-blind, placebo-controlled, multiple-dose, single-dose, multiple-dose tolerance, pharmacokinetic phase i clinical trials in healthy subjects. Single administration setting 60mg, 180mg, 360mg, 540mg, 720mg, 960mg, 1080mg, total 7 dose groups; multiple administrations set 180mg, 360mg, 540mg, 720mg for 4 dose groups; carrying out a food influence test in a 480mg dose group, and simultaneously collecting a urine sample and a feces sample in the first period of the food influence test for researching the recovery rate and the drug metabolic conversion; to evaluate the tolerance of single and multiple administrations, pharmacokinetics, drug metabolic conversion and recovery rate and the influence of food on the pharmacokinetics of the complex tablet of the present invention in healthy subjects, and to preliminarily evaluate the pharmacodynamics.
According to calculation of PK results of single administration and multiple administrations, after the compound disclosed by the invention is orally taken for 240mg, the EXP3174 exposure amount in a human body is not lower than the total active ingredient exposure amount in the human body after losartan is orally taken for 100mg, and the LBQ657 exposure amount in the human body is not lower than the LBQ657 exposure amount in the human body after LCZ 696200 mg is orally taken; after 480mg of the compound of the invention is orally taken, the exposure of EXP3174 in a human body is not less than the total exposure of active ingredients in the human body after 200mg of losartan is orally taken, and the exposure of LBQ657 in the human body is not less than the exposure of LBQ657 in the human body after LCZ 696400 mg is orally taken.
Therefore, after the compound is applied to patients with heart failure and hypertension, the compound shows expected clinical treatment effect from the aspects of internal medicine generation and medicine effect.
Comparative example 1
Figure PCTCN2021100465-APPB-000029
Figure PCTCN2021100465-APPB-000030
The granulation process comprises the following steps: and (4) dry granulating.
The dissolution results of this formulation, measured at ph1.2, are slow, as shown in the following table:
Figure PCTCN2021100465-APPB-000031
comparative example 2
Figure PCTCN2021100465-APPB-000032
The granulation process comprises the following steps: dissolving the compound of example 3 and poloxamer 188 in dichloromethane, placing crospovidone XL and microcrystalline cellulose in a fluidized bed, controlling the air inlet temperature to be 50-70 ℃ and the material temperature to be 40-50 ℃, performing spray drying, mixing with magnesium stearate, and tabletting.
The obtained tablets are stored for 2 months at 40 +/-2 ℃ and 75 +/-5% RH, and impurity detection is carried out by an HPLC method, and the following results show that the product prepared by the formula process has poor stability.
Figure PCTCN2021100465-APPB-000033
Figure PCTCN2021100465-APPB-000034
Comparative example 3
Adopt toThe following formula is compared with the example formula, the dissolution at pH1.2 is obviously better than that of the comparative example of 301-305 by adopting the formula of the invention, the dissolution properties of the example 9 and the example 11 are similar, and the result AUC of the in vivo metabolite effect is found by the dog pK experimentlastClose to each other, can effectively ensure the drug effect.
The experimental prescription and results are as follows:
Figure PCTCN2021100465-APPB-000035
Figure PCTCN2021100465-APPB-000036
Figure PCTCN2021100465-APPB-000037
pk data in beagle
PK parameters Example 9 x 2 305 Example 11
EXP3174 Unit Mean Mean Mean
AUC last h*ng/mL 4644.9 3729.2 4271.1
LBQ657 Unit Mean Mean Mean
AUC last h*ng/mL 4002.5 3473.5 3827.8
Remarking: LBQ657 is active metabolite of shakubatu, and 2 tablets.
As can be seen from the above experimental results, in the formulation of the present invention, when the complex is presentaWhen 60mg or 120mg of the pharmaceutical composition is selected, the combination of low-substituted hydroxypropyl cellulose and crospovidone is preferred under the condition that microcrystalline cellulose and lactose are selected as supporting agents, and the dissolution effect of the pharmaceutical composition is superior to that of the single use or other proportion combination of croscarmellose sodium, low-substituted hydroxypropyl cellulose, crospovidone and carboxymethyl starch sodium; and from the comparison of batches 305, 306 and examples 9, 11, the preferred mass ratio of low substituted hydroxypropylcellulose to crospovidone is 1.75-2.25:1, more preferably 2: 1.
aThe amount of the complex is expressed as the anhydrous free acid C46H 50ClN 7O 7Meter
Comparative example 4
The following formulation and example 9 were used to find the in vivo metabolite effect AUC by monkey pK assaylastClose to each other, can effectively ensure the corresponding drug effect.
The experimental prescription and results are as follows:
Figure PCTCN2021100465-APPB-000038
pk data in animals (monkeys)
Figure PCTCN2021100465-APPB-000039
Remarking: LBQ657 is active metabolite of shakubatu, and 4 tablets.
The results of the animal in vivo PK data show that 401 lots of EXP3174 exposure are closer to 4 samples of 60mg of example 9 process.
Comparative example 5
The experimental prescription and results are as follows:
402 in proportion% 403 In proportion%
Example 3 composite 266.4 52.35 266.4 52.35
Microcrystalline cellulose 83 16.31 83 16.31
Anhydrous lactose 53 10.41 53 10.41
Sodium starch glycolate 27 5.31 / /
Croscarmellose sodium 33 6.48 / /
Cross-linked polyvidone 33 6.48 33 6.48
Low-substituted hydroxypropyl cellulose / / 60 11.79
Silicon dioxide 8 1.57 8 1.57
Magnesium stearate 5.5 1.08 5.5 1.08
Figure PCTCN2021100465-APPB-000040
Combining the effects of comparative examples 4 and 5, the Applicant has found that, based on the recipes of examples 14 and 15 (batch 401), and 402 and 403, when the compound is usedaIn the pharmaceutical composition 240mg, 1.8: 1-2.2: 1 (specifically, 1.9: 1, 2:1, 2.1: 1), the composition preferably contains 8 to 12% of carboxymethyl starch sodium, 8 to 12% of croscarmellose sodium and 8 to 12% of crospovidone, wherein the crospovidone is used in the pharmaceutical composition, and the amount of crospovidone used in the pharmaceutical composition is 8 to 12% of the composition, and the composition is difficult to achieve corresponding dissolution and is expected to be difficult to achieve corresponding in vivo dissolution effects compared with the selection of other proportions of the combination of the carboxymethyl starch sodium, the croscarmellose sodium and the crospovidone, or the combination of the crospovidone and the low-substituted hydroxypropyl cellulose and other proportions of the microcrystalline cellulose and lactose.
aThe amount of the complex is expressed as the anhydrous free acid C46H 50ClN 7O 7Meter
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.

Claims (16)

  1. A pharmaceutical composition of a complex, wherein the structural units of the complex are as follows:
    (aEXP3174·bAHU377)·xCa·nA
    wherein a and b are 1: 0.25-4; x is a number between 0.5 and 3; a refers to water, methanol, ethanol, 2-propanol, acetone, ethyl acetate, methyl-tert-butyl ether, acetonitrile, toluene, dichloromethane; n is a number between 0 and 3;
    the pharmaceutical composition contains one or a mixture of more than two of low-substituted hydroxypropyl cellulose, crospovidone, carboxymethyl starch sodium, croscarmellose sodium and pregelatinized starch in any proportion, and the usage amount of the pharmaceutical composition is 4-50%; and one or more other adjuvants.
  2. The compound pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises low-substituted hydroxypropylcellulose and crospovidone, the usage amount of the low-substituted hydroxypropylcellulose in the pharmaceutical composition is 17% -30%, and the usage amount of the crospovidone in the pharmaceutical composition is 8% -20%; or the pharmaceutical composition contains carboxymethyl starch sodium, croscarmellose sodium and crospovidone, wherein the use amount of the carboxymethyl starch sodium in the pharmaceutical composition is 4% -12%, the use amount of the croscarmellose sodium in the pharmaceutical composition is 4% -12%, and the use amount of the crospovidone in the pharmaceutical composition is 4% -12%.
  3. A composite pharmaceutical composition according to claim 2, wherein the ratio of low substituted hydroxypropylcellulose to crospovidone is 1: 1-3: 1, the sum of the weight of the two is preferably 25 to 40 percent; or the sum of the weight of the carboxymethyl starch sodium, the croscarmellose sodium and the crospovidone is 15 to 35 percent of the usage amount in the pharmaceutical composition.
  4. A pharmaceutical composition according to claim 3, wherein when the ratio of the compound in the pharmaceutical composition is 25% to 30%, preferably the ratio of the low substituted hydroxypropylcellulose to crospovidone is 1.75: 1-2.25: 1, more preferably 2: 1; or when the proportion of the complex in the pharmaceutical composition is 40% -50%, the pharmaceutical composition contains carboxymethyl starch sodium, croscarmellose sodium and crospovidone, the use amount of the carboxymethyl starch sodium in the pharmaceutical composition is 8-12%, the use amount of the croscarmellose sodium in the pharmaceutical composition is preferably 8-12%, and the use amount of the crospovidone in the pharmaceutical composition is 8-12%.
  5. A complex pharmaceutical composition according to any one of claims 1 to 4, wherein said one or more further excipients comprise one or more fillers, lubricants and coating agents;
    the filler comprises one or a mixture of more than two of microcrystalline cellulose, lactose, mannitol and calcium hydrophosphate in any proportion, and the usage amount of the filler is 16-60% of the weight of the pharmaceutical composition;
    the lubricant comprises one or a mixture of more than two of silicon dioxide, stearic acid, magnesium stearate, polyethylene glycol and hydrogenated castor oil, and the mass of the lubricant is 1-3% of the weight of the pharmaceutical composition;
    the coating agent comprises a gastric soluble coating agent.
  6. A compound pharmaceutical composition according to claim 5, wherein the filler comprises a mixture of microcrystalline cellulose and lactose, and the mass ratio of microcrystalline cellulose to lactose is 1: 1-5: 1, the total mass of the microcrystalline cellulose and the lactose accounts for 16-60 percent of the weight of the pharmaceutical composition.
  7. The compound pharmaceutical composition as claimed in claim 5, wherein when the proportion of the compound in the pharmaceutical composition is 25% -30%, the mass ratio of the microcrystalline cellulose to the lactose is 1.5: 1-5: 1, preferably the total mass of microcrystalline cellulose and lactose is 17-45% by weight of the pharmaceutical composition.
  8. The compound pharmaceutical composition as claimed in claim 5, wherein when the proportion of the compound in the pharmaceutical composition is 40% -50%, the mass ratio of the microcrystalline cellulose to the lactose is 1.8: 1-2.2: 1, preferably the total mass of microcrystalline cellulose and lactose is 17-45% by weight of the pharmaceutical composition.
  9. A complex pharmaceutical composition according to any one of claims 1 to 8, wherein said complex is administered as the anhydrous free acid C46H 50ClN 7O 7Calculated) is 20-50% of the weight of the medicine composition.
  10. A complex pharmaceutical composition according to any one of claims 1 to 8, wherein said complex is administered as the anhydrous free acid C46H 50ClN 7O 7Calculated) is 30mg, 60mg, 90mg, 120mg, 150mg, 180mg, 210mg, 240mg, 270mg, 300 mg.
  11. A pharmaceutical composition according to any one of claims 1 to 10, wherein the pharmaceutical composition is a solid formulation suitable for oral administration, preferably a tablet or capsule for oral administration.
  12. A complex pharmaceutical composition according to any one of claims 1 to 11, wherein a: the values of b include 1:0.25,1: 0.5,1: 1,1: 1.5,1: 2,1: 2.5,1: 3,1: 3.5,1: 4;
    further preferably, the building blocks of the complex are as follows:
    (EXP3174·AHU377)·xCa·nH 2O
    or
    Figure PCTCN2021100465-APPB-100001
    Wherein x is a number between 0.5 and 2; n is a number between 0 and 3; further preferred x comprises 0.5, 1, 1.5, 2.
  13. A complex pharmaceutical composition according to any one of claims 1 to 11, wherein the structural units of said complex are as follows:
    (EXP3174·AHU377)·1.5Ca·nH 2O
    or
    (EXP3174·AHU377)·2Ca·nH 2O
    Wherein n is any value between 1 and 3, and is further preferably: n includes 0.5, 1, 1.5, 2, 2.5, 3.
  14. A complex pharmaceutical composition according to any one of claims 1 to 11, wherein said complex comprises:
    (EXP3174·AHU377)·1.5Ca·1H 2O；
    (EXP3174·AHU377)·1.5Ca·1.5H 2O；
    (EXP3174·AHU377)·1.5Ca·2H 2O；
    (EXP3174·AHU377)·1.5Ca·2.5H 2O；
    (EXP3174·AHU377)·1.5Ca·3H 2O；
    (EXP3174·AHU377)·2Ca·1H 2O；
    (EXP3174·AHU377)·2Ca·1.5H 2O；
    (EXP3174·AHU377)·2Ca·2H 2O；
    (EXP3174·AHU377)·2Ca·2.5H 2O；
    (EXP3174·AHU377)·2Ca·3H 2O。
  15. a pharmaceutical composition of the combination according to any one of claims 1-11, wherein the pharmaceutical composition is prepared by a direct compression process or a dry granulation process.
  16. Use of a pharmaceutical composition according to any one of claims 1 to 15 for the preparation of a medicament for the prevention and/or treatment of hypertension, heart failure, hypertension and heart failure.
CN202180004442.1A 2020-06-18 2021-06-17 Pharmaceutical composition of compound and preparation method thereof Active CN114096530B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211269494.4A CN116036079A (en) 2020-06-18 2021-06-17 Pharmaceutical composition of compound and preparation method thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020105581410 2020-06-18
CN202010558141 2020-06-18
CN202110490430 2021-05-06
CN2021104904306 2021-05-06
PCT/CN2021/100465 WO2021254409A1 (en) 2020-06-18 2021-06-17 Pharmaceutical composition of complex and preparation method therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211269494.4A Division CN116036079A (en) 2020-06-18 2021-06-17 Pharmaceutical composition of compound and preparation method thereof

Publications (2)

Publication Number Publication Date
CN114096530A true CN114096530A (en) 2022-02-25
CN114096530B CN114096530B (en) 2022-11-15

Family

ID=79268475

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180004442.1A Active CN114096530B (en) 2020-06-18 2021-06-17 Pharmaceutical composition of compound and preparation method thereof
CN202211269494.4A Pending CN116036079A (en) 2020-06-18 2021-06-17 Pharmaceutical composition of compound and preparation method thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211269494.4A Pending CN116036079A (en) 2020-06-18 2021-06-17 Pharmaceutical composition of compound and preparation method thereof

Country Status (3)

Country Link
CN (2) CN114096530B (en)
TW (1) TWI784575B (en)
WO (1) WO2021254409A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115444829A (en) * 2022-10-25 2022-12-09 南京康川济医药科技有限公司 Sacubitril valsartan sodium gastric-retention sustained-release tablet and preparation method thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024027779A1 (en) * 2022-08-04 2024-02-08 深圳信立泰药业股份有限公司 New crystal form of arni compound, preparation method therefor, and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017125031A1 (en) * 2016-01-20 2017-07-27 深圳信立泰药业股份有限公司 Angiotensin ii receptor antagonist metabolite and nep inhibitor composite, and preparation method thereof
CN110801452A (en) * 2015-03-12 2020-02-18 深圳信立泰药业股份有限公司 Pharmaceutical composition containing allisartan isoproxil hydrolysate or hydrolysate salt thereof and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057882A1 (en) * 2005-11-09 2007-12-26 Novartis Ag DOUBLE ACTION COMPOUNDS OF ANGIOTENSIN RECEPTOR BLOCKERS AND NEUTRAL ENDOPEPTIDASE INHIBITORS
CN105503760A (en) * 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 Crystalline ARB-NEPi dicationic compound and preparation method and application thereof
CN106146472A (en) * 2015-04-15 2016-11-23 苏州朗科生物技术有限公司 A kind of A Lishatan compound of double action
CN106138041A (en) * 2015-04-15 2016-11-23 苏州朗科生物技术有限公司 A kind of Losartan compound of double action
CN105669581B (en) * 2015-11-09 2017-03-22 成都苑东生物制药股份有限公司 Angiotensin receptor antagonist/neutral endopeptidase inhibitor composite
US20220226285A1 (en) * 2019-05-30 2022-07-21 Shenzhen Salubris Pharmaceuticals Co., Ltd. Treatment Method Using A Complex of Angiotensin II Receptor Antagonist Metabolite and NEP Inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110801452A (en) * 2015-03-12 2020-02-18 深圳信立泰药业股份有限公司 Pharmaceutical composition containing allisartan isoproxil hydrolysate or hydrolysate salt thereof and application thereof
WO2017125031A1 (en) * 2016-01-20 2017-07-27 深圳信立泰药业股份有限公司 Angiotensin ii receptor antagonist metabolite and nep inhibitor composite, and preparation method thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115444829A (en) * 2022-10-25 2022-12-09 南京康川济医药科技有限公司 Sacubitril valsartan sodium gastric-retention sustained-release tablet and preparation method thereof
CN115444829B (en) * 2022-10-25 2023-08-22 南京康川济医药科技有限公司 Sakuba/valsartan sodium gastric retention sustained release tablet and preparation method thereof

Also Published As

Publication number Publication date
TWI784575B (en) 2022-11-21
CN116036079A (en) 2023-05-02
CN114096530B (en) 2022-11-15
WO2021254409A1 (en) 2021-12-23
TW202200123A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
EP2974720B1 (en) Mosapride sustained-release preparation for providing pharmacological clinical effects with once-a-day administration
US20090208579A1 (en) Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
JP6058000B2 (en) Sustained release formulation of ivabradine or a pharmaceutically acceptable salt thereof
JP5295123B2 (en) New pharmaceutical composition
KR20210016436A (en) Pharmaceutical combinations, compositions, and formulations containing a glucokinase activator and a PPAR receptor activator, and methods and uses of the same
US20060159753A1 (en) Matrix type sustained-release preparation containing basic drug or salt thereof
CN114096530B (en) Pharmaceutical composition of compound and preparation method thereof
CN109875972B (en) Olmesartan medoxomil and amlodipine pharmaceutical composition
WO2019142207A1 (en) Pharmaceutical compositions comprising ibrutinib
JP7046978B2 (en) Compositions with improved water solubility and bioavailability
JP5241511B2 (en) Pharmaceutical composition with improved dissolution
KR101093781B1 (en) Solid pharmaceutical composition of moxifloxacin comprising ph adjustment agent
WO2019230937A1 (en) Solid oral dosage form having excellent dissolution properties
KR20180024505A (en) Formulation of fenofibric acid with improved bioavailability
EP3886817A1 (en) Pharmaceutical composition comprising ramipril and indapamide
JP2022514040A (en) Tamsulosin hydrochloride-containing pharmaceutical composition having excellent acid resistance and a method for producing the same.
CN114340614B (en) Oseltamivir preparation
JP6903252B2 (en) Enteric-coated preparation containing xanthine oxidase inhibitor
JP2011527314A (en) Eprosartan composition
CN115957189A (en) Ambrisentan preparation and preparation method thereof
EP4079296A1 (en) A bilayer tablet formulation comprising amorphous dapagliflozin and metformin
EP4212150A1 (en) A bilayer tablet composition comprising amorphous dapagliflozin and metformin
WO2023136797A2 (en) A bilayer tablet composition comprising amorphous dapagliflozin and metformin
TW202300138A (en) Lacosamide pharmaceutical composition, preparation method and application thereof
US20100152269A1 (en) Modified-release formulations of azabicyclo derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Area A, 4th Floor, Digital Peninsula, No. 2, Hongliu Road, Fubao Community, Fubao Street, Futian District, Shenzhen, Guangdong, 518017

Applicant after: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd.

Address before: 518040 37th floor, chegongmiao Lvjing Plaza, 6009 Shennan Avenue, Futian District, Shenzhen City, Guangdong Province

Applicant before: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant